O-[2-(苯氧基)乙基]羟胺 | 73941-29-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: O-[2-(苯氧基)乙基]羟胺
• 英文名称: O-(2-phenoxyethyl)hydroxylamine
• 英文别名: (2-phenoxyethoxy)amine；O-(2-phenoxy-ethyl)-hydroxylamine；O-(2-Phenoxy-aethyl)-hydroxylamin；2-phenoxy-ethyl-hydroxylamine；O-<2-Phenoxy-ethyl>-hydroxylamin
• CAS: 73941-29-4
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: HWKGEDJHAMSGKI-UHFFFAOYSA-N

物化性质

• 沸点：
  286.7±23.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  O-[2-(苯氧基)乙基]羟胺 在 sodium hydroxide 、 对甲苯磺酸 、 溶剂黄146 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 18.33h， 生成 6-(3,5-Dimethylphenyl)sulfanyl-5-isopropyl-1-(2-phenoxyethoxy)pyrimidine-2,4-dione
  参考文献：
  名称：

  Synthesis and Anti-HIV-1 Activity of a Series of 1-Alkoxy-5-alkyl-6-(arylthio)uracils

  摘要：

  A series of 1-alkoxy-5-alkyl-6-(arylthio)uracils was synthesized and tested for their ability to inhibit HIV-1 replication. Treatment of 2-alkyl-3,3-bis(methylthio)acryloyl chlorides (5a-e) with AgOCN in benzene followed by reaction of the resulting isocyanates 6a-e with an appropriate alkoxyamine gave N-alkoxy-N'-((2-alkyl-3,3-bis(methylthio (10a-z) in good to excellent yields. Cyclization of 10a-z in AcOH containing st catalytic amount of p-TsOH produced 1-alkaxy-5-alkyl-6-(methylthio)uracils (11a-z). Oxidation of 11a-z with 3-chloroperoxybenzoic acid in CH2Cl2 resulted in high yields of 1-alkoxy-5-alkyl-6-(methylsulfonyl)uracils (12a-x and 12z) and 1-(benzyloxy)-6-(methylsulfinyl)thymine (12y), which were subsequently reacted with an appropriate arenethiol in ethanolic NaOH solution to afford 1-alkoxy-5-alkyl-6-(arylthio)uracils (14-49). Substitution at the 3- and 5-positions of the C-6-(phenylthio) ring by two methyl groups significantly increased its original anti-HIV-l activity (EC50: 6-((3,5-dimethylphenyl)thio)-5-isopropyl-1-propoxyuracil (18), 0.064 mu M; 6-((3,5-dimethylphenyl)thio)-1-(3-hydroxypropoxy)-5-isopropyluracil (23), 0.19 mu M). Among the various alkoxy substituents at the N-1, the propoxy group was the most beneficial for improving the anti-HIV-1 activity. The 1-propoxy derivative 18 proved to be the most potent inhibitor of HIV-1 replication, followed by the 1-(3-hydroxypropoxy) derivative 23. Introduction of an isopropyl group at C-5 of the uracil base also remarkably enhanced the activity. When compound 18 was incubated with a rat liver homogenate preparation, no metabolite was observed, thus confirming the metabolic stability of the N-O bond in these 1-alkoxyuracils.

  DOI：

  10.1021/jm9607921
• 作为产物：
  描述：

  己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯 在 咪唑 偶氮二甲酸二异丙酯 、 N-hydroxyphthalimide resin 、 三苯基膦 、 甲胺 作用下， 以 二氯甲烷 、 甲醇 、 氯仿 为溶剂， 反应 26.0h， 以84%的产率得到O-[2-(苯氧基)乙基]羟胺
  参考文献：
  名称：

  通过碱催化的Mitsunobu反应平行合成伯和仲O-烷基羟胺的新型支持试剂

  摘要：

  O-烷基羟胺在药物化学和化学生物学中的应用领域不断增长，促使人们寻求平行合成方法。一种基于固相的固相方法已得到优化，该方法是使用Mitsunobu反应，然后进行甲基氨基分解，对一种新型的负载型N-羟基邻苯二甲酰亚胺试剂进行醇烷基化。这项研究指出了接头的重要性以及Mitsunobu反应的特定碱基效应。可以使用多种醇以中等至高产率得到高纯度的各种O-烷基羟胺。

  DOI：

  10.1021/jo050722e

文献信息

• Synthesis of 6-substituted 1-alkoxy-5-alkyluracils
  作者：Dae-Kee Kim、Young-Woo Kim、Key H. Kim

  DOI：10.1002/jhet.5570340148

  日期：1997.1

  Synthesis of 6-substituted 1-alkoxy-5-alkyluracils 2a-c have been achieved from readily accessible 2-alkyl-3,3-di(methylthio)acryloyl chlorides 4a,b in high overall yields. Treatment of 4a,b with silver cyanate followed by reaction of the resulting isocyanates 5a,b with an appropriate alkoxyamine afforded N-alkoxy-N′-[2-alkyl-3,3-di(methylthio)acryloyl]ureas 6a,b in 85–88% yields. Cyclization of 6a

  从易于获得的2-烷基-3，3-二（甲硫基）丙烯酰氯4a，b已经以高的总收率实现了6-取代的1-烷氧基-5-烷基尿嘧啶2a-c的合成。的治疗4A，4B与氰酸银，然后将所得的异氰酸酯的反应5a，5b中与得到适当的烷氧基胺ñ -烷氧基- ñ ' - [2-烷基3,3-二（甲硫基）丙烯酰基]脲6A，6B在85–88％的产量。6a，b在含甲磺酸的乙酸中环化，然后用3-氯过氧苯甲酸氧化，得到高产率的1-烷氧基-5-烷基-6-（甲基磺酰基）尿嘧啶9a，b。9a，b与叠氮化钠，苯硫醇或苯硒醇的亲核加成消除反应生成6-叠氮基-1-丁氧基胸腺嘧啶（2a，98％），5-乙基-1-（2-苯氧基乙氧基）-6-（苯硫基）尿嘧啶（2b，95％）或5-乙基-1-（2-苯氧基乙氧基）-6-（苯基硒烯基）尿嘧啶（2c，91％）。
• Oximes short-acting CB1 receptor agonists
  作者：Michael S. Malamas、Jimit Girish Raghav、Xiaoyu Ma、Chandrashekhar Honrao、JodiAnne T. Wood、Othman Benchama、Han Zhou、Srikrishnan Mallipeddi、Alexandros Makriyannis

  DOI：10.1016/j.bmc.2018.08.003

  日期：2018.10

  conformation was coincided with that of the AM11542 CB1 agonist-bound structure, stabilizing the CB1 receptor at the active-state (agonistic functional effect). We have selected oxime trans-8a based on its potency for CB1, and favorable pharmacodynamic profile, such as fast onset and predictable duration of pharmacological action, for evaluation in pre-clinical models of anorexia nervosa.

  新肟短效CB1激动剂通过引入内部肟和极性基团在Δ的C3烷基尾探索8 -THC。研究的范围是彻底改变该化合物的两个重要的物理化学性质疏水性（log P）和拓扑表面积（tPSA），它们在组织分布和螯合（储库效应）中起着至关重要的作用。对于CB1证明亚纳摩尔亲和力在疏水性显着减少键合成类似物，（ClogP~2.5-3.5 VSΔ9.09 8 -THC-DMH），并发现其功能为激动剂（反式-oximes）或中性拮抗剂（顺-肟）在cAMP功能测定中。所有肟类似物均对CB2受体表现出可比的亲和力，但令人惊讶的是，它们被发现对CB2起反向激动剂的作用。在行为学研究（即痛觉缺失，低体温）反式-肟8A显示出可预测的快速起效（〜20分钟）和药理作用（〜180分钟）的短的持续时间，而相比之下，Δ的非常时间延长8 -THC-DMH（ > 24小时），从而限制了与CB1受体持续激活相关的严重精神副作用的可能性。我们
• Diaminopyrimidines and combination therapies effective for treatment of P-glycoprotein positive cancers
  申请人：——

  公开号：US20040006042A1

  公开（公告）日：2004-01-08

  The present invention provides compounds of Formula II: 1

  本发明提供了II式化合物：1
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES
  申请人：DNA Script

  公开号：US20210300961A1

  公开（公告）日：2021-09-30

  Methods for preparing 3′-O-amino-2′-deoxyribonucleoside-5′-triphosphates with reduced 3′-hydroxy-2′-deoxyribonucleoside-5′-triphosphate contamination by converting 3′-(N-acetone-oxime)-2′-deoxynucleoside triphosphate to 3′-O-amine-2′-deoxynucleoside triphosphate by treatment with an aryl-oxyamine and compositions produced therefrom.

  制备方法，用于制备含有较少3'-羟基-2'-脱氧核苷酸-5'-三磷酸污染的3'-O-氨基-2'-脱氧核苷酸-5'-三磷酸，通过将3'-(N-丙酮肟)-2'-脱氧核苷酸三磷酸转化为3'-O-氨基-2'-脱氧核苷酸三磷酸，并由此产生的组合物。